Items Tagged ‘myelofibrosis’

June 7th, 2016

Jakafi Significantly Improves Long-Term Outcomes in Myelofibrosis

By

The agent Jakafi® (ruxolitinib) has demonstrated significant improvements in long-term outcomes for patients diagnosed with myelofibrosis. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Myelofibrosis (MF) is a type of blood cancer known as a myeloproliferative neoplasm that is chronic and progressive in nature. It involves the […]

View full entry

Tags: 2016, asco, blood cancer, COMFORT 1, jakafi, myelofibrosis, Myeloproliferative Neoplasms MPN, News


April 27th, 2016

Pacritinib Development in Myelofibrosis Placed on Clinical Hold by the FDA

By

The investigative agent, pacritinib, being evaluated for treatment of myelofibrosis has been placed on full clinical hold by the United States Food and Drug Administration (FDA). All trials including treatment involving pacritinib have been stopped, and the New Drug Application (NDA) to the FDA for pacritinib has been withdrawn.1 Myelofibrosis is a type of blood […]

View full entry

Tags: clinical hold, fda, mpn, myelofibrosis, myeloproliferative neoplasm, Myeloproliferative Neoplasms MPN, NDA, News, pacritinib, withdrawn


February 10th, 2016

Year in Review: Myeloproliferative Neoplasms

By

Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening complications, and are at risk of progression to acute leukemia. The development and approval of the JAK2 inhibitor Jakafi® (Ruxolitinib) has led to more effective management of these symptoms in many patients with PV, positively […]

View full entry

Tags: essential thrombocythemia, jakafi, mpn, myelofibrosis, Myeloproliferative Neoplasms MPN, News, polycythemia vera, research, review


April 21st, 2015

What you Need to Know about Itching and Myeloproliferative Neoplasms

By

What you Need to Know about Itching and Myeloproliferative Neoplasms If you have been diagnosed with myelofibrosis or polycythemia vera, you may have experienced itching as a side effect. Itching occurs as a result of the activity of cytokines (small proteins involved in cell signaling) associated with myeloproliferative neoplasms (MPNs) and because a certain type […]

View full entry

Tags: itching, jakafi, mpn, myelofibrosis, Myeloproliferative Neoplasms MPN, News, polycythemia vera, ruxolutinib


March 25th, 2015

Pacritinib May Be Effective against Myelofibrosis without Risk of Myelosuppression

By

The investigational agent pacritinib appears active against myelofibrosis without the risk of myelosuppression, a common side effect of many drugs used to treat myelofibrosis and other myeloproliferative neoplasms (MPN). The developers of pacritinib, CTI BioPharma Corp and Baxter International Inc, announced these findings from a Phase III clinical trial called PERSIST-1. Myelofibrosis is a type […]

View full entry

Tags: blood cancer, mpn, myelofibrosis, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, pacritinib, PERSIST-1, research


January 22nd, 2015

Myeloproliferative Neoplasms: Making Progress in Polycythemia Vera and Myelofibrosis

By

Myeloproliferative neoplasms (MPN) are a related group of blood cancers. In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. The three main types of MPN are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In addition to developing on its own, myelofibrosis may also develop as a […]

View full entry

Tags: jakafi, mpn, myelofibrosis, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV


June 18th, 2014

Have a Question about Myeloproliferative Neoplasms? Join us on July 23rd

By

CancerConnect announces the opportunity to engage with a myeloproliferative neoplasm (MPN) expert, on July 23rd, 2014. In this Ask the Expert Series, questions will be answered about polycythemia vera, essential thrombocythemia and myelofibrosis in the MPN Community on CancerConnect. CancerConnect is a safe and private online support community for cancer patients and caregivers. Join the […]

View full entry

Tags: essential thrombocythemia, mpn, myelofibrosis, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, polycytehmia vera